PMID- 12009766
OWN - NLM
STAT- MEDLINE
DCOM- 20020523
LR  - 20091119
IS  - 0014-4886 (Print)
IS  - 0014-4886 (Linking)
VI  - 175
IP  - 1
DP  - 2002 May
TI  - Sequential interactions of fibroblast growth factor-2, brain-derived neurotrophic 
      factor, neurotrophin-3, and their receptors define critical periods in the 
      development of cochlear ganglion cells.
PG  - 138-51
AB  - We studied the interactions of neurotrophin-3 (NT3) with brain-derived 
      neurotrophic factor (BDNF), fibroblast growth factor-2 (FGF-2), and their effects 
      on tyrosine kinase C (TrkC) expression during cochlear ganglion development. 
      Otocysts were explanted from white leghorn chicken embryos at stages when the 
      neuronal precursors normally start to migrate. Cultures were fed with various 
      combinations of NT3, BDNF, and FGF-2. NT3 appeared to have a greater effect on 
      neurite outgrowth than on migration and was enhanced by BDNF. The results from in 
      situ hybridization and immunostaining for TrkC receptor revealed up-regulation of 
      the mRNA and protein by combining NT-3 and BDNF. NT-3 combined with FGF-2 
      produced down-regulation of receptor. Neutralizing antibody to NT3 had an 
      inhibitory effect on neuronal development, suggesting that endogenous NT3 is 
      normally active during the period examined. The findings suggest an interactive 
      role of NT3 in early neuronal development. The trophic synergism of NT3 and BDNF 
      may result from up-regulation of TrkC. This hypothesis is consistent with 
      immunostaining in the embryonic basilar papilla, which localized TrkC to the 
      initial axonal invasion sites. While the growth factors each produce particular 
      trophic effects, the interactions of these factors define a critical sequence of 
      developmental events based on modulation of receptor expression.
CI  - Copyright 2002 Elsevier Science (USA).
FAU - Hossain, W Amin
AU  - Hossain WA
AD  - Department of Neuroscience, University of Connecticut Health Center, Farmington, 
      Connecticut 06030-3401, USA.
FAU - Brumwell, C L
AU  - Brumwell CL
FAU - Morest, D K
AU  - Morest DK
LA  - eng
GR  - R01NS29613/NS/NINDS NIH HHS/United States
GR  - T32DC00025/DC/NIDCD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Exp Neurol
JT  - Experimental neurology
JID - 0370712
RN  - 0 (Antibodies, Blocking)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Neurotrophin 3)
RN  - 0 (RNA, Messenger)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - EC 2.7.10.1 (Receptor, trkC)
SB  - IM
MH  - Animals
MH  - Antibodies, Blocking/pharmacology
MH  - Brain-Derived Neurotrophic Factor/pharmacology/*physiology
MH  - Cell Movement/drug effects
MH  - Cells, Cultured
MH  - Chick Embryo
MH  - Drug Interactions/physiology
MH  - Fibroblast Growth Factor 2/pharmacology/*physiology
MH  - Immunohistochemistry
MH  - In Situ Hybridization
MH  - Neurites/drug effects
MH  - Neurons/cytology/drug effects
MH  - Neurotrophin 3/antagonists & inhibitors/pharmacology/*physiology
MH  - RNA, Messenger/metabolism
MH  - Receptor, trkC/genetics/*metabolism
MH  - Spiral Ganglion/cytology/drug effects/*embryology/physiology
MH  - Stem Cells/cytology/drug effects
MH  - Time Factors
EDAT- 2002/05/16 10:00
MHDA- 2002/05/25 10:01
CRDT- 2002/05/16 10:00
PHST- 2002/05/16 10:00 [pubmed]
PHST- 2002/05/25 10:01 [medline]
PHST- 2002/05/16 10:00 [entrez]
AID - S0014488602978726 [pii]
AID - 10.1006/exnr.2002.7872 [doi]
PST - ppublish
SO  - Exp Neurol. 2002 May;175(1):138-51. doi: 10.1006/exnr.2002.7872.